A new article published on 6 October 2023 in the Journal of the British Pharmacological Society titled"Dose rationale for gabapentin and tramadol in paediatric patients with chronic pain" co-authored by Prof Adriana Ceci and Dr Mariagrazia Felisi, respectively CVBF’s Scientific Advisor and Quality Assurance Head, shedding light on the dearth of substantial evidence regarding the [...]
On 27 June 2023, Mariagrazia Felisi, our Quality Assurance Head and Internal Auditor, co-chairing the "AICRO Clinical Trial Center Working Group", opened and led the workshop, titled "Applicazione del regolamento UE sulla sperimentazione clinica in Italia: esperienze a confronto", took place at the “Salone di Rappresentanza dell’Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo” [...]
Giovanni Migliaccio, the Scientific Director of CVBF, recently participated at the MEP Interest Group 2023 Conference organized by the European Alliance for Transformative Therapies (TRANSFORM) and held at the European Parliament on 12 October 2023. The event provided a platform for profound deliberation on various critical issues concerning highly specialized Advanced therapy medicinal products, known [...]
In the ever-advancing world of clinical research, staying at the forefront of knowledge and practices is imperative. On 12 September 2023, our CEO, Donato Bonifazi who is a member of the Coordinating Group at the (the EMA network of paediatric research), participated in the EUCROF Paediatric Training at the Children Hospital “Bambino Gesù” in Rome, [...]
Bonka Georgieva, CVBF's Project Manager, presented at the "ERICA & EJP RD Joint Conference" held in Amsterdam. The event served as a platform for advancing coordination and support in rare disease research. CVBF, in collaboration with EATRIS, leads Task 19.1: Accelerating Translation. The Innovation Management Toolbox (IMT), developed under Subtask 19.1.1, stands as a testament [...]
Arianna Bertolani, our Head of Project and Development, will participate, as a speaker at the 16th Foresight Training Course entitled "Repurposing to cover unmet needs: the current scenario in Europe and the proposed changes to the Pharmaceutical Legislation" organised by Fondazione per la Ricerca Farmacologica Gianni Benzi ONLUS and Università degli Studi di Bari and, [...]
Phase 1 trials, be they conducted on healthy volunteers or patients, focus on generation of initial knowledge on tolerability, safety and PK/PD.. These trials determine the maximum tolerated dose without unacceptable side effects and may involve some risks, even after passing preclinical testing. While typically conducted with healthy subjects, Phase 1 trials may include severely [...]
In today's fast-paced digital world, a company's online presence is often its first point of contact with customers. It's not just a virtual business card but a dynamic platform that reflects your brand, services, and values. We understand the significance of this connection, which is why we are thrilled to announce the launch of our [...]
We are thrilled to invite you to watch the CVBF History Timeline Video to have a glimpse of our journey through the remarkable milestones and achievements of CVBF from 2000 to the present day. Join us as we delve into the pivotal moments that have shaped CVBF. Witness how CVBF's dedication to excellence [...]
Join us for an unforgettable experience at the 2023 iCAN Summit! We are excited to announce that our CEO, as a member of the iCAN Advisory Board, will be participating in the upcoming 2023 iCAN Summit in La Jolla, San Diego, California. This highly anticipated event, presented by Jumo Health, will take place from July [...]
